|Bid||6.02 x 800|
|Ask||6.03 x 900|
|Day's range||5.98 - 6.05|
|52-week range||5.41 - 38.50|
|Beta (5Y monthly)||3.85|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
What happened Shares of Seres Therapeutics (NASDAQ: MCRB) were soaring 17.1% higher as of 3:09 p.m. EDT on Wednesday. The big gain came after the company announced that it has achieved its target enrollment of 300 participants in a phase 3 study evaluating SER-109 in treating recurrent C.
As every investor would know, you don't hit a homerun every time you swing. But it should be a priority to avoid...
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -29.27% and 19.75%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?